Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen
Although the introduction of novel agents improved the survival outcomes in patients with multiple myeloma (MM), some patients died within one year (early mortality, EM) following diagnosis. In this study, we evaluated the EM rate, and investigated the risk factors associated with EM in MM patients....
Gespeichert in:
| Veröffentlicht in: | BMC cancer 2016-08, Vol.16 (1), p.613-613, Article 613 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 613 |
|---|---|
| container_issue | 1 |
| container_start_page | 613 |
| container_title | BMC cancer |
| container_volume | 16 |
| creator | Jung, Sung-Hoon Cho, Min-Seok Kim, Hee Kyung Kim, Seok Jin Kim, Kihyun Cheong, June-Won Kim, Soo-Jeoong Kim, Jin Seok Ahn, Jae-Sook Kim, Yeo-Kyeoung Yang, Deok-Hwan Kim, Hyeoung-Joon Lee, Je-Jung |
| description | Although the introduction of novel agents improved the survival outcomes in patients with multiple myeloma (MM), some patients died within one year (early mortality, EM) following diagnosis. In this study, we evaluated the EM rate, and investigated the risk factors associated with EM in MM patients.
Retrospective data from 542 patients who were initially treated with a novel agent-containing regimen were analyzed.
The median overall survival (OS) for the entire cohort was 56.5 months. The median OS in the 2010-2014 group was longer than in the 2002-2009 group (59.2 months vs. 49.1 months, P = 0.054). The rate of EM was 13.8 %, and the most common causes of EM were infection and comorbidity. In multivariate analysis, the age-adjusted Charlson comorbidity index (ACCI ≥ 4), low body mass index (BMI |
| doi_str_mv | 10.1186/s12885-016-2645-y |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4977683</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A468815745</galeid><sourcerecordid>A468815745</sourcerecordid><originalsourceid>FETCH-LOGICAL-c492t-26de282aba5714dbac4cb2d89d46f82995047f6c544283e36fdd7eb2d6fa97033</originalsourceid><addsrcrecordid>eNpVks9u1DAQhyMEoqXwAFyQJSQEh4CdtWPnUqmq-FOpElKBszXrTLIGx15sp0tegmcm25Rq9-SR5ptPntGvKF4y-p4xVX9IrFJKlJTVZVVzUU6PilPGJSsrTuXjg_qkeJbST0qZVFQ9LU4qKShrRHNa_L2x6RfpwOQQE4GUgrGQsSU7mzcEIbqJDCFmcDZPxHqyhWzR57QAw-iy3Tokw4QuDEB2m0B2GJHkiHeecdvF4POCA_HhFh2B_k5h5gZYb31PIvZ2QP-8eNKBS_ji_j0rfnz6-P3yS3n99fPV5cV1aXhT5XnbFitVwRqEZLxdg-FmXbWqaXndqappBOWyq43gvFIrXNVd20qcibqDRtLV6qw4X7zbcT1ga-bvRHB6G-0AcdIBrD7ueLvRfbjVvJGyVnvB23tBDL9HTFkPNhl0DjyGMWmmGBVCUiFn9PWC9uBQW9-F2Wj2uL7gtVJMSC5m6t0Rtb8N_sk9jCnpq283x-ybA3aD4PImBTdmG3w6BtkCmhhSitg9bMio3kdILxHSc4T0PkJ6mmdeHZ7mYeJ_Zlb_ANuhxNw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1810557057</pqid></control><display><type>article</type><title>Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen</title><source>SpringerOpen</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>SpringerLink (Online service)</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><source>PubMed Central Open Access</source><creator>Jung, Sung-Hoon ; Cho, Min-Seok ; Kim, Hee Kyung ; Kim, Seok Jin ; Kim, Kihyun ; Cheong, June-Won ; Kim, Soo-Jeoong ; Kim, Jin Seok ; Ahn, Jae-Sook ; Kim, Yeo-Kyeoung ; Yang, Deok-Hwan ; Kim, Hyeoung-Joon ; Lee, Je-Jung</creator><creatorcontrib>Jung, Sung-Hoon ; Cho, Min-Seok ; Kim, Hee Kyung ; Kim, Seok Jin ; Kim, Kihyun ; Cheong, June-Won ; Kim, Soo-Jeoong ; Kim, Jin Seok ; Ahn, Jae-Sook ; Kim, Yeo-Kyeoung ; Yang, Deok-Hwan ; Kim, Hyeoung-Joon ; Lee, Je-Jung ; Korean Multiple Myeloma Working Party (KMMWP)</creatorcontrib><description>Although the introduction of novel agents improved the survival outcomes in patients with multiple myeloma (MM), some patients died within one year (early mortality, EM) following diagnosis. In this study, we evaluated the EM rate, and investigated the risk factors associated with EM in MM patients.
Retrospective data from 542 patients who were initially treated with a novel agent-containing regimen were analyzed.
The median overall survival (OS) for the entire cohort was 56.5 months. The median OS in the 2010-2014 group was longer than in the 2002-2009 group (59.2 months vs. 49.1 months, P = 0.054). The rate of EM was 13.8 %, and the most common causes of EM were infection and comorbidity. In multivariate analysis, the age-adjusted Charlson comorbidity index (ACCI ≥ 4), low body mass index (BMI < 20 kg/m(2)), thrombocytopenia, and renal failure were significantly associated with EM. The presence of none, 1, or ≥ 2 factors was associated with a 4.1 %, 14.3 %, or 27.4 % risk of EM (P < 0.001), respectively. The median OS times were significantly different depending on the presence of factors associated with EM (P < 0.001).
In conclusion, the ACCI (≥ 4), low BMI, thrombocytopenia and renal failure were strong predictors for EM in the novel agent era. The results of this study will help to identify patients at high risk for EM, and may be helpful to more accurately predict prognosis of MM patients in the novel-agent era.</description><identifier>ISSN: 1471-2407</identifier><identifier>EISSN: 1471-2407</identifier><identifier>DOI: 10.1186/s12885-016-2645-y</identifier><identifier>PMID: 27501959</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - therapeutic use ; Body Mass Index ; Drug therapy ; Female ; Humans ; Male ; Middle Aged ; Mortality ; Multiple myeloma ; Multiple Myeloma - drug therapy ; Multiple Myeloma - mortality ; Prognosis ; Retrospective Studies ; Risk Factors ; South Korea ; Survival Analysis</subject><ispartof>BMC cancer, 2016-08, Vol.16 (1), p.613-613, Article 613</ispartof><rights>COPYRIGHT 2016 BioMed Central Ltd.</rights><rights>The Author(s). 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c492t-26de282aba5714dbac4cb2d89d46f82995047f6c544283e36fdd7eb2d6fa97033</citedby><cites>FETCH-LOGICAL-c492t-26de282aba5714dbac4cb2d89d46f82995047f6c544283e36fdd7eb2d6fa97033</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977683/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977683/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27501959$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jung, Sung-Hoon</creatorcontrib><creatorcontrib>Cho, Min-Seok</creatorcontrib><creatorcontrib>Kim, Hee Kyung</creatorcontrib><creatorcontrib>Kim, Seok Jin</creatorcontrib><creatorcontrib>Kim, Kihyun</creatorcontrib><creatorcontrib>Cheong, June-Won</creatorcontrib><creatorcontrib>Kim, Soo-Jeoong</creatorcontrib><creatorcontrib>Kim, Jin Seok</creatorcontrib><creatorcontrib>Ahn, Jae-Sook</creatorcontrib><creatorcontrib>Kim, Yeo-Kyeoung</creatorcontrib><creatorcontrib>Yang, Deok-Hwan</creatorcontrib><creatorcontrib>Kim, Hyeoung-Joon</creatorcontrib><creatorcontrib>Lee, Je-Jung</creatorcontrib><creatorcontrib>Korean Multiple Myeloma Working Party (KMMWP)</creatorcontrib><title>Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen</title><title>BMC cancer</title><addtitle>BMC Cancer</addtitle><description>Although the introduction of novel agents improved the survival outcomes in patients with multiple myeloma (MM), some patients died within one year (early mortality, EM) following diagnosis. In this study, we evaluated the EM rate, and investigated the risk factors associated with EM in MM patients.
Retrospective data from 542 patients who were initially treated with a novel agent-containing regimen were analyzed.
The median overall survival (OS) for the entire cohort was 56.5 months. The median OS in the 2010-2014 group was longer than in the 2002-2009 group (59.2 months vs. 49.1 months, P = 0.054). The rate of EM was 13.8 %, and the most common causes of EM were infection and comorbidity. In multivariate analysis, the age-adjusted Charlson comorbidity index (ACCI ≥ 4), low body mass index (BMI < 20 kg/m(2)), thrombocytopenia, and renal failure were significantly associated with EM. The presence of none, 1, or ≥ 2 factors was associated with a 4.1 %, 14.3 %, or 27.4 % risk of EM (P < 0.001), respectively. The median OS times were significantly different depending on the presence of factors associated with EM (P < 0.001).
In conclusion, the ACCI (≥ 4), low BMI, thrombocytopenia and renal failure were strong predictors for EM in the novel agent era. The results of this study will help to identify patients at high risk for EM, and may be helpful to more accurately predict prognosis of MM patients in the novel-agent era.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Body Mass Index</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - mortality</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>South Korea</subject><subject>Survival Analysis</subject><issn>1471-2407</issn><issn>1471-2407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVks9u1DAQhyMEoqXwAFyQJSQEh4CdtWPnUqmq-FOpElKBszXrTLIGx15sp0tegmcm25Rq9-SR5ptPntGvKF4y-p4xVX9IrFJKlJTVZVVzUU6PilPGJSsrTuXjg_qkeJbST0qZVFQ9LU4qKShrRHNa_L2x6RfpwOQQE4GUgrGQsSU7mzcEIbqJDCFmcDZPxHqyhWzR57QAw-iy3Tokw4QuDEB2m0B2GJHkiHeecdvF4POCA_HhFh2B_k5h5gZYb31PIvZ2QP-8eNKBS_ji_j0rfnz6-P3yS3n99fPV5cV1aXhT5XnbFitVwRqEZLxdg-FmXbWqaXndqappBOWyq43gvFIrXNVd20qcibqDRtLV6qw4X7zbcT1ga-bvRHB6G-0AcdIBrD7ueLvRfbjVvJGyVnvB23tBDL9HTFkPNhl0DjyGMWmmGBVCUiFn9PWC9uBQW9-F2Wj2uL7gtVJMSC5m6t0Rtb8N_sk9jCnpq283x-ybA3aD4PImBTdmG3w6BtkCmhhSitg9bMio3kdILxHSc4T0PkJ6mmdeHZ7mYeJ_Zlb_ANuhxNw</recordid><startdate>20160808</startdate><enddate>20160808</enddate><creator>Jung, Sung-Hoon</creator><creator>Cho, Min-Seok</creator><creator>Kim, Hee Kyung</creator><creator>Kim, Seok Jin</creator><creator>Kim, Kihyun</creator><creator>Cheong, June-Won</creator><creator>Kim, Soo-Jeoong</creator><creator>Kim, Jin Seok</creator><creator>Ahn, Jae-Sook</creator><creator>Kim, Yeo-Kyeoung</creator><creator>Yang, Deok-Hwan</creator><creator>Kim, Hyeoung-Joon</creator><creator>Lee, Je-Jung</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160808</creationdate><title>Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen</title><author>Jung, Sung-Hoon ; Cho, Min-Seok ; Kim, Hee Kyung ; Kim, Seok Jin ; Kim, Kihyun ; Cheong, June-Won ; Kim, Soo-Jeoong ; Kim, Jin Seok ; Ahn, Jae-Sook ; Kim, Yeo-Kyeoung ; Yang, Deok-Hwan ; Kim, Hyeoung-Joon ; Lee, Je-Jung</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c492t-26de282aba5714dbac4cb2d89d46f82995047f6c544283e36fdd7eb2d6fa97033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Body Mass Index</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - mortality</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>South Korea</topic><topic>Survival Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jung, Sung-Hoon</creatorcontrib><creatorcontrib>Cho, Min-Seok</creatorcontrib><creatorcontrib>Kim, Hee Kyung</creatorcontrib><creatorcontrib>Kim, Seok Jin</creatorcontrib><creatorcontrib>Kim, Kihyun</creatorcontrib><creatorcontrib>Cheong, June-Won</creatorcontrib><creatorcontrib>Kim, Soo-Jeoong</creatorcontrib><creatorcontrib>Kim, Jin Seok</creatorcontrib><creatorcontrib>Ahn, Jae-Sook</creatorcontrib><creatorcontrib>Kim, Yeo-Kyeoung</creatorcontrib><creatorcontrib>Yang, Deok-Hwan</creatorcontrib><creatorcontrib>Kim, Hyeoung-Joon</creatorcontrib><creatorcontrib>Lee, Je-Jung</creatorcontrib><creatorcontrib>Korean Multiple Myeloma Working Party (KMMWP)</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMC cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jung, Sung-Hoon</au><au>Cho, Min-Seok</au><au>Kim, Hee Kyung</au><au>Kim, Seok Jin</au><au>Kim, Kihyun</au><au>Cheong, June-Won</au><au>Kim, Soo-Jeoong</au><au>Kim, Jin Seok</au><au>Ahn, Jae-Sook</au><au>Kim, Yeo-Kyeoung</au><au>Yang, Deok-Hwan</au><au>Kim, Hyeoung-Joon</au><au>Lee, Je-Jung</au><aucorp>Korean Multiple Myeloma Working Party (KMMWP)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen</atitle><jtitle>BMC cancer</jtitle><addtitle>BMC Cancer</addtitle><date>2016-08-08</date><risdate>2016</risdate><volume>16</volume><issue>1</issue><spage>613</spage><epage>613</epage><pages>613-613</pages><artnum>613</artnum><issn>1471-2407</issn><eissn>1471-2407</eissn><abstract>Although the introduction of novel agents improved the survival outcomes in patients with multiple myeloma (MM), some patients died within one year (early mortality, EM) following diagnosis. In this study, we evaluated the EM rate, and investigated the risk factors associated with EM in MM patients.
Retrospective data from 542 patients who were initially treated with a novel agent-containing regimen were analyzed.
The median overall survival (OS) for the entire cohort was 56.5 months. The median OS in the 2010-2014 group was longer than in the 2002-2009 group (59.2 months vs. 49.1 months, P = 0.054). The rate of EM was 13.8 %, and the most common causes of EM were infection and comorbidity. In multivariate analysis, the age-adjusted Charlson comorbidity index (ACCI ≥ 4), low body mass index (BMI < 20 kg/m(2)), thrombocytopenia, and renal failure were significantly associated with EM. The presence of none, 1, or ≥ 2 factors was associated with a 4.1 %, 14.3 %, or 27.4 % risk of EM (P < 0.001), respectively. The median OS times were significantly different depending on the presence of factors associated with EM (P < 0.001).
In conclusion, the ACCI (≥ 4), low BMI, thrombocytopenia and renal failure were strong predictors for EM in the novel agent era. The results of this study will help to identify patients at high risk for EM, and may be helpful to more accurately predict prognosis of MM patients in the novel-agent era.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>27501959</pmid><doi>10.1186/s12885-016-2645-y</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-2407 |
| ispartof | BMC cancer, 2016-08, Vol.16 (1), p.613-613, Article 613 |
| issn | 1471-2407 1471-2407 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4977683 |
| source | SpringerOpen; MEDLINE; DOAJ Directory of Open Access Journals; SpringerLink (Online service); PubMed Central; EZB Electronic Journals Library; PubMed Central Open Access |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Body Mass Index Drug therapy Female Humans Male Middle Aged Mortality Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - mortality Prognosis Retrospective Studies Risk Factors South Korea Survival Analysis |
| title | Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T17%3A53%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20factors%20associated%20with%20early%20mortality%20in%20patients%20with%20multiple%20myeloma%20who%20were%20treated%20upfront%20with%20a%20novel%20agents%20containing%20regimen&rft.jtitle=BMC%20cancer&rft.au=Jung,%20Sung-Hoon&rft.aucorp=Korean%20Multiple%20Myeloma%20Working%20Party%20(KMMWP)&rft.date=2016-08-08&rft.volume=16&rft.issue=1&rft.spage=613&rft.epage=613&rft.pages=613-613&rft.artnum=613&rft.issn=1471-2407&rft.eissn=1471-2407&rft_id=info:doi/10.1186/s12885-016-2645-y&rft_dat=%3Cgale_pubme%3EA468815745%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1810557057&rft_id=info:pmid/27501959&rft_galeid=A468815745&rfr_iscdi=true |